To catch Antarctic toothfish, you must bait your hook with Peruvian squid and cast it into the depths of the Ross Sea. This is what a team of Ukrainians did on a fishing trip near Antarctica. But sometimes, Mother Nature trips you up. Sometimes, you catch a hopbeard plunderfish.

In 2009-2010, Ukrainian mariners happened to pull up three fish that looked unfamiliar. Further analysis found that they were a previously undiscovered species, dubbed the hopbeard plunderfish and described in a study published online April 29 in the journal ZooKeys. The fish bear the scientific name Pogonophryne neyelovi.

The strange-looking denizens of the deep have brownish-splotched bodies and are shaped somewhat like tadpoles, especially when young, according to the study. They have sharp dorsal fins that extend along the top of their bodies and strange "barbels," which resemble dirty Q-tips, that extend from their chins.

The longest of the three specimens measured 14 inches (35.5 centimeters). And they really like to live in the deep they were pulled from depths of up to 4,560 feet (1,390 meters).

The fish have large livers, which fill up to 35 percent of their abdomen. Whether or not that means these sea creatures could drink like, well, fish, is unknown.

If you're fond of the hopbeard, just wait until you meet its cousins. The genus Pogonophryne, also known as the short-barbeled plunderfish, has a total of 22 species. These fish also live in the frigid waters surrounding Antarctica. Some of them live in the Ross Sea, like the hopbeard, which is found offshore of Antarctica's Ross Ice Shelf.

Currently, next to nothing is known about their behavior, diet or what they do down there in the depths.

Email Douglas Main or follow him @Douglas_Main. Follow us @OAPlanet, Facebook or Google+. Original article on LiveScience's OurAmazingPlanet.

Copyright 2013 LiveScience, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Excerpt from:
New Deep-Sea Fish Species Found in Antarctica

Recommendation and review posted by Bethany Smith

Public release date: 9-May-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, May 9, 2013Insomnia and other sleep disturbances are common among perimenopausal and postmenopausal women and may increase their risk of coronary heart disease (CHD) and cardiovascular disease (CVD). Evidence that a combination of altered sleep duration and insomnia among women ages 50-79 doubled their risk of both CHD and CVD over a period of more than 10 years is presented in an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Women's Health website at http://www.liebertpub.com/jwh.

In "Sleep Duration, Insomnia, and Coronary Heart Disease among Postmenopausal Women in the Women's Health Initiative," Megan Sands-Lincoln, PhD, MPH and a team of researchers from leading medical institutions across the U.S. gathered self-reported data on sleep duration and insomnia in 86,329 women 50-79 years of age. Shorter (<5 hours) and longer (>10 hours) sleep duration and insomnia were associated with higher incidence of CHD and CVD over 10.3 years, and when considered together, the interaction risk of insomnia and sleep duration was significant.

"This is the first study to investigate interactions of sleep duration with insomnia in relation to increased risk of CHD and CVD in postmenopausal women," says Susan G. Kornstein, MD, Editor-in-Chief of Journal of Women's Health, Executive Director of the Virginia Commonwealth University Institute for Women's Health, Richmond, VA, and President of the Academy of Women's Health.

###

About the Journal

Journal of Women's Health, published monthly, is a core multidisciplinary journal dedicated to the diseases and conditions that hold greater risk for or are more prevalent among women, as well as diseases that present differently in women. The Journal covers the latest advances and clinical applications of new diagnostic procedures and therapeutic protocols for the prevention and management of women's healthcare issues. Complete tables of content and a sample issue may be viewed on the Journal of Women's Health website at http://www.liebertpub.com/jwh. Journal of Women's Health is the Official Journal of the Academy of Women's Health and the Society for Women's Health Research.

About the Academy

Academy of Women's Health is an interdisciplinary, international association of physicians, nurses, and other health professionals who work across the broad field of women's health, providing its members with up-to-date advances and options in clinical care that will enable the best outcomes for their women patients. The Academy's focus includes the dissemination of translational research and evidence-based practices for disease prevention, diagnosis, and treatment of women across the lifespan.

Excerpt from:
Do insomnia and disrupted sleep during menopause increase a woman's risk of heart disease?

Recommendation and review posted by Bethany Smith

SAN DIEGO, May 9, 2013 /PRNewswire/ --Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $38.5 million for the first quarter of 2013, an increase of 158% compared to revenue of $14.9 million for the first quarter of 2012. First quarter 2013 revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostics services operating segment grew more than 38% as compared to the fourth quarter of 2012.

"The volume of 35,000 MaterniT21 PLUS tests accessioned in the first quarter shows that Sequenom CMM continued to take advantage of its first mover position in the non-invasive prenatal diagnostic (NIPT) market by increasing its penetration of the NIPT market and maintaining its dominant market share. The recent announcement that Sequenom CMM had accessioned over 100,000 MaterniT21 PLUS test samples since the test was launched in October of 2011 is further evidence of the remarkable success of this testing service," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "Furthermore, we are making progress in our negotiations within the payor community, with more than 70 million patients now under coverage who have access to the MaterniT21 PLUS test."

Revenues from the Sequenom CMM diagnostics services operating segment grew to more than $29 million in the first quarter of 2013, up from $4.8 million in the prior year period. As of the first quarter 2013, diagnostic revenue accounted for more than 75% of total revenue, up from 63% in the fourth quarter of 2012.

Revenues from the Sequenom CMM diagnostics services operating segment are recorded primarily on a cash basis. Approximately 35% of diagnostic revenue reported for the first quarter 2013 is attributable to tests performed in the same period. Approximately 65% of the diagnostic revenue reported in the first quarter 2013 is related to payment collected on tests performed in prior periods. First quarter 2013 revenues from the genetic analysis operating segment decreased 7% from the same period in 2012, due to a softening in consumables orders, partially due to timing.

Total cost of revenues increased to $24.5 million for the first quarter of 2013, compared to $10.3 million for the prior year period. Cost of revenues increased primarily due to the significant increase in Sequenom CMM's test volumes and costs to support increased testing capacity, as total tests accessioned increased 250% to more than 44,500 patient samples during the first quarter of 2013. Approximately 35,000 of those patient samples tested during the first quarter were MaterniT21 PLUS test samples, compared to approximately 25,000 in the fourth quarter of 2012, growing 40% sequentially.

Overall gross margin for the first quarter of 2013 was 36% as compared to gross margin of 31% for the first quarter of 2012. This improvement is attributable primarily to the positive contribution from the Sequenom CMM diagnostic services business resulting from higher cash collections during the quarter and improved efficiencies in processing patient samples. Gross margin for the Sequenom CMM diagnostics services business in the first quarter of 2013 was approximately 28%, as compared to a negative gross margin in the first quarter of 2012. Gross margin for the genetic analysis business for the first quarter of 2013 was 63% compared to 66% for the prior year period.

Total operating expenses for the first quarter of 2013 were $41.0 million, as compared to total operating expenses of $28.9 million for the first quarter of 2012, down sequentially from total operating expenses of $42.0 million for the fourth quarter of 2012. Selling and marketing expenses increased to $13.7 million for the first quarter of 2013 from $9.7 million year-over-year, resulting primarily from higher labor costs associated with the expansion of the Sequenom CMM sales force and increased headcount to support commercial operations. Research and development expenses increased to $13.8 million for the first quarter of 2013, as compared to $11.8 million in the first quarter of 2012, related primarily to increased labor and supplies and costs relative to the expansion into the Sequenom CMM North Carolina facilities.

General and administrative expenses for the first quarter of 2013 were $13.5 million, as compared to $7.4 million for the first quarter of 2012, primarily due to increased legal expenses associated with patent litigation, increased collection costs due to the increase in diagnostics revenue and increased headcount to support the Company's operations. Total stock-based compensation expense was $3.1 million for the first quarter of 2013, an increase from $2.9 million in stock-based compensation recorded for the first quarter of 2012.

Net loss for the first quarter of 2013 was $29.4 million, or $0.26 per share, as compared to net loss of $24.4 million, or $0.22 per share, for the same period in 2012. Net cash used in operating activities was $19.7 million for the first quarter of 2013, compared to $23.3 million in the same period in the prior year. The Company also used cash for capital investments of $4.1 million and debt repayments of $1.8 million during the first quarter of 2013. As of March 31, 2013, total cash, cash equivalents, and marketable securities were $151.1 million.

"We are pleased to see sequential improvements in volume, revenue and margin during the quarter, an indication of steady growth and sustained momentum in 2013," said Paul V. Maier, Sequenom's CFO. "As we complete the process of moving our billing and collections processes in-house, we anticipate even greater control in monitoring our payments from payors and improved workflows that will help us improve our collection cycle and reimbursement."

Continued here:
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013

Recommendation and review posted by Bethany Smith

Scientists find mutation that results in red or purple marks Breakthrough described as 'complete game changer' Condition could now be prevented in children

By Nick Mcdermott

PUBLISHED: 01:55 EST, 9 May 2013 | UPDATED: 03:48 EST, 9 May 2013

Genetics: Birthmarks may become a thing of the past thanks to the efforts of researchers in the U.S. File picture

Unsightly birthmarks that affect thousands of newborns each year could soon be eradicated.

Scientists have found a genetic mutation which is responsible for port wine stain marks, and claim the discovery is a 'complete game changer' which they hope will lead to new preventative treatments.

One in every 300 children born in Britain has the condition which results in red or purple marks on the body, most commonly on the neck or face.

They are caused by the abnormal development of blood vessels in the skin, and the birthmark may become thicker, darken and develop a raised appearance in later years.

A research team in the U.S. has now proved the condition occurs because of a gene mutation, which occurs after conception.

Although laser treatment can lighten their appearance, the birthmarks are not curable. The genetic mutation discovered by researchers at Kennedy Krieger Institute in Baltimore is also responsible for Sturge-Weber syndrome (SWS), a rare disorder that affects the eyes and brain, and is associated to port wine stain.

Read the original post:
Genetic breakthrough means birthmarks could soon be eradicated

Recommendation and review posted by Bethany Smith

Hereford Genetics; The next decade...where are you going? - Dr David Johnston
Animal Genetics Breeding Unit (AGBU) Principal Scientist Dr David Johnston speaks about Hereford Genetics; The next decade...where are you going? at the He...

By: HerefordsAustralia

Here is the original post:
Hereford Genetics; The next decade...where are you going? - Dr David Johnston - Video

Recommendation and review posted by Bethany Smith

Immunology Lecture 11 Part 5 Genetics of Immunoglobulin Diversity
Immunoglobulins are important part of immune systems. These molecules are instrumental for defending against viruses, bacteria, and helminths etc. These mole...

By: Mobeen Syed

Continue reading here:
Immunology Lecture 11 Part 5 Genetics of Immunoglobulin Diversity - Video

Recommendation and review posted by Bethany Smith

Skittles - Genetics
It #39;s Bring-Your-Infant-To-Work Day! Directed By: Allison Collins Written By: Henry Held Edited By: Colton Moyer.

By: VanMoyerVids

Read the original post:
Skittles - Genetics - Video

Recommendation and review posted by Bethany Smith

Alex Jones David Icke - GMOs, Human Genetics and Pedophilia
British author David Icke has written 20 books and traveled to over 55 countries since 1990. His books reveal how a hidden hand is behind world-changing even...

By: DismantleTheMatrix

See more here:
Alex Jones

Recommendation and review posted by Bethany Smith

Genetics 004
Back cross, test cross, law of segregation, dihybrid cross grade x.

By: Sandeep Changlani

Continue reading here:
Genetics 004 - Video

Recommendation and review posted by Bethany Smith

Minerals, Genetics and Q A
More info on minerals. More info on genetics.

By: bios3training

Excerpt from:
Minerals, Genetics and Q

Recommendation and review posted by Bethany Smith

DNA Genetics Exodus Kush Marijuana Clones
Two leggy DNA Genetics Exodus Kush marijuana clones are just entering the first week of flowering. These plants are known to stretch substantially during the...

By: Matt Mernagh

More:
DNA Genetics Exodus Kush Marijuana Clones - Video

Recommendation and review posted by Bethany Smith

11.5 Population Genetics

By: Barbra Bedwell

Continue reading here:
11.5 Population Genetics - Video

Recommendation and review posted by Bethany Smith

The Genetics Course Pack
Washington University School of Medicine (Class of 2016) 1st Year Class Show.

By: WUSM2016

Continue reading here:
The Genetics Course Pack - Video

Recommendation and review posted by Bethany Smith

UK Biobank genetics
Dr Cathie Sudlow, Chief Scientist at UK Biobank, talks about the work of UK Biobank in genetics.

By: Andrew Trehearne

Read more:
UK Biobank

Recommendation and review posted by Bethany Smith

Time Capsule Tuesday Letter Reading by Peter Tishler, MD, Division of Genetics
In 1963, Peter Bent Brigham Hospital leadership sealed a time capsule that included letters from notable hospital staff of that era. In this video, Peter Tishler, MD, Division of Genetics,...

By: Brighamandwomens

Read the rest here:
Time Capsule Tuesday Letter Reading by Peter Tishler, MD, Division of Genetics - Video

Recommendation and review posted by Bethany Smith

Genetics Show Cousins Across the World
UC Davis geneticist Graham Coop discusses new work showing that people across Europe, and probably the world, are cousins who share many ancestors in just th...

By: UCDavis

Read more:
Genetics Show Cousins Across the World - Video

Recommendation and review posted by Bethany Smith

Human Genetics Project 2013 Explanation behind Starcraft 2 #39;s Marine
This is my project for BIOL1309 These claims are all theory, not actual fact.

By: Randy Vo

View post:
Human Genetics Project 2013 Explanation behind Starcraft 2's Marine - Video

Recommendation and review posted by Bethany Smith

VERTEBRAL SUBLUXATIONS AND HUMAN GENETICS
Each of the 100 trillion cells in the human body (with the exception of red blood cells) contains the entire human genome mdash;all of the information necessary to build a human being. This information...

By: rhinochirotv

Read the original:
VERTEBRAL SUBLUXATIONS AND HUMAN GENETICS - Video

Recommendation and review posted by Bethany Smith

2013 Focus Genetics Private Treaty Sale Introduction
http://www.focusgenetics.com.

By: clearvisionimaging

View original post here:
2013 Focus Genetics Private Treaty Sale Introduction - Video

Recommendation and review posted by Bethany Smith

Gene Therapy Final
My First Project.

By: annieszmanda

Visit link:
Gene Therapy Final - Video

Recommendation and review posted by Bethany Smith

Salt Lake City, UT (PRWEB) May 09, 2013

Academic and industry leaders in gene and cell therapy will be featured at an American Society of Gene & Cell Therapy (ASGCT) Media Event in Salt Lake City, Utah, on Thursday, May 16th, from 9:40 am 10:20 am, followed immediately by a one-on-one interview session with ASGCT scientists at 10:20 am 11:45 am. The American Society of Gene and Cell Therapy boasts of a membership consisting of experts bringing clinical breakthroughs to a wide array of diseases and disorders. These advances are positioned to bring meaningful therapies to children and adults, including those suffering from both inherited and acquired illnesses.

The event will profile exciting clinical results reported in patients suffering from serious and often deadly diseases such as liver cancer, ovarian cancer, lymphoma, hemophilia, and many more. For further details, please consider the following examples:

ASGCT scientists will report dramatic results in children and adult patients with Leukemia using gene-modified immune cells that kill tumors specifically while sparing normal tissues in patients. After injected into the blood stream, these cells performed a seek-and-destroy mission of the cancer cells in patients that led to complete remission of their diseases.

Late stage clinical development of live viruses that reproduce only in cancer cells but not normal tissues which, after injection into cancer patients, acted like laser-guided smart bombs that destroyed the tumors without major side effects.

Groundbreaking work will be reported for the orphan disease Aromatic L-Amino Acid Decarboxylase (AADC). This is a progressive fatal disorder whereby children lose all of their motor abilities and die by the age of six years as their parents helplessly stand by. Children who could not sit or control their head movement were treated with gene therapy and have demonstrated remarkable improvement.

Hemophilia researchers have successfully treated men living with this bleeding disorder with gene therapy. These patients, who had spent their entire lives being injected with life-saving clotting factors, have discontinued protein replacement altogether. Investigators have also treated children born with devastating genetic illnesses such as Pompe Disease.

The press event will take place in Room 150ABC in the Salt Palace Convention Center.

Members of the media will also receive complimentary full-access registration to the ASGCT 16th Annual Meeting at the Salt Palace Convention Center. Media representatives who wish to attend may contact ASGCT directly at 414.278.1341 or info(at)asgct(dot)org.

The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, http://www.asgct.org.

See the original post:
A Media Event on Clinical Developments in Gene and Cell Therapy

Recommendation and review posted by Bethany Smith

Big Data:The Promise and the Challenge for Personalized Medicine
Jonathan Sheldon Ph.D explains what Oracle are doing to meet the big data challenges in translational medicine at the Personalized Medicine World Congress (P...

By: OracleHealthSciences

Read the original:
Big Data:The Promise and the Challenge for Personalized Medicine - Video

Recommendation and review posted by sam

Personalized Medicine by Bridget Bruno
This is part of the lesson I taught to a group of ESL students about my topic for the 2013 Student BioExpo. Somehow, only a brief part of my presentation rec...

By: ariquenosiempre1

See the original post here:
Personalized Medicine by Bridget Bruno - Video

Recommendation and review posted by sam

Personalized Medicine by Bridget Bruno. Royal High School
I presented a lesson about Personalized Medicine to a group of middle and high school students, most of them are part of the ESL program. Unfortunately, only 1:08 minutes of my class recorded 🙁

By: StudentBioExpo

Read the original post:
Personalized Medicine by Bridget Bruno. Royal High School - Video

Recommendation and review posted by sam

Patient Stratification: Personalized Medicine using Ariana Pharma KEM technology
Learn how Ariana Pharma #39;s KEM data mining technology can be applied to patient stratification and clinical data intelligence. Ariana is your partner for delivering the promise of personalized...

By: ArianaPharma

See the article here:
Patient Stratification: Personalized Medicine using Ariana Pharma KEM® technology - Video

Recommendation and review posted by sam